Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | CCND3 | P30281 | 2/20 | 0.35 |
| ▸ | CCNK | O75909 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | C5AR1 | P21730 | 4/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | CCND2 | P30279 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2848559 | 1.00 | MAPT (0.43) | MAPTTRPV1MTORPDE10ACCND3 | |
| SCHEMBL2451471 | 0.91 | CYP3A4 (0.34) | MAPTTRPV1PDE10AJAK2JAK3 | |
| SCHEMBL2446909 | 0.88 | ROCK2 (0.39) | TRPV1JAK2CDK4 | |
| SCHEMBL2477810 | 0.88 | ROCK2 (0.39) | TRPV1JAK2CDK4 | |
| SCHEMBL2477814 | 0.88 | ROCK2 (0.39) | TRPV1JAK2CDK4 | |
| SCHEMBL2483931 | 0.81 | SYK (0.32) | JAK2CDK4 | |
| SCHEMBL2483928 | 0.81 | SYK (0.32) | JAK2CDK4 | |
| SCHEMBL2842254 | 0.81 | MAPT (0.51) | MAPTTRPV1MTORPDE10ACCND3 | |
| SCHEMBL2839484 | 0.80 | MAPT (0.46) | MAPTTRPV1MTORPDE10ACCND3 | |
| SCHEMBL2844684 | 0.79 | MAPT (0.46) | MAPTTRPV1MTORPDE10ACCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130495-A1 | COMPOUNDS 563 | BACE1, PSEN1, PSEN2 | MAPT 10/4885TRPV1 3250/4885MTOR 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.